SCHEMBL580414

SCHEMBL580414

Clc1nnc(-c2ccccc2)c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.49
ALDH1A1 P00352 6/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
KDM4E B2RXH2 3/20 0.49
HPGD P15428 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
PDE5A O76074 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
ALOX15 P16050 1/20 0.49
PDE1A P54750 1/20 0.49
PDE1B Q01064 1/20 0.49
PDE3B Q13370 1/20 0.49
PDE1C Q14123 1/20 0.49
PDE3A Q14432 1/20 0.49
HSD17B10 Q99714 1/20 0.49
HTT P42858 4/20 0.48
LMNA P02545 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29537275 1.00 MAPT (0.49) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL31359722 0.88 KMT2A (0.57) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL1396090 0.88 KMT2A (0.57) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL4864061 0.86 HTT (0.60) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL10876406 0.85 GOT1 (0.75) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL1268020 0.84 ESR1 (0.49) MAPTALDH1A1SMN1; SMN2HPGDCYP1A2
SCHEMBL27938933 0.84 KDR (0.45) MAPTALDH1A1SMN1; SMN2HPGDCYP1A2
SCHEMBL7904780 0.84 ALDH1A1 (0.60) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL10662227 0.83 SMN1; SMN2 (0.58) MAPTALDH1A1SMN1; SMN2KDM4EHPGD
SCHEMBL8551380 0.82 LMNA (0.45) MAPTALDH1A1SMN1; SMN2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-57048972-A None JP disclosed
JP-10109936-A None JP disclosed
JP-56053659-A None JP disclosed
CN-115160378-B Red-light organic electrophosphorescent material and preparation method and application thereof 安徽工业大学 2024-08-20 CN disclosed
CN-115010765-B Red-light organic electrophosphorescent material and preparation method and application thereof 安徽工业大学 2024-08-20 CN disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 US disclosed
CN-116710453-A Kinase inhibitors and uses thereof 璧辰医药技术股份有限公司 2023-09-05 CN disclosed
EP-4192582-A1 KINASE INHIBITORS AND USES THEREOF ABM Therapeutics Corporation (US) 2023-06-14 EP disclosed
CN-115160378-A Red light organic electrophosphorescent material and preparation method and application thereof 安徽工业大学 2022-10-11 CN disclosed
JP-H10109936-A AGENT FOR TREATING AND PREVENTING DIABETIC NEUROPATHY MITSUBISHI CHEM CORP 1998-04-28 JP disclosed
EP-0825187-A1 Condensed pyridazinyl guanidines, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-02-25 EP disclosed
US-5643911-A CEREBROVASCULAR DISEASE MITSUBISHI CHEMICAL CORPORATION (JP) 1997-07-01 US disclosed
US-5462941-A 1-(cyclohexylalkylamino)-4-(phenyl, thienyl, or furyl) phthalazines; anti-platelet agglutination agents for treatment or prevention of cerebro- or cardiovascular disorders MITSUBISHI CHEMICAL CORPORATION (JP) 1995-10-31 US disclosed
EP-0449203-B1 4-Phenylphthalazine derivatives MITSUBISHI CHEM IND (JP) 1994-12-07 EP disclosed
EP-0534443-A1 3,6-Disubstituted pyridazine derivatives Mitsubishi Chemical Corporation (JP) 1993-03-31 EP disclosed
US-5089494-A 4-PHENYLPHTHALAZINE DERIVATIVES WHICH INHIBIT PLATELET AGGREGATION MITSUBISHI KASEI CORPORATION (JP) 1992-02-18 US disclosed
EP-0449203-A1 4-Phenylphthalazine derivatives Mitsubishi Chemical Corporation (JP) 1991-10-02 EP disclosed
JP-S5748972-A 4-PHENYLPHTHALAZINE DERIVATIVE MITSUBISHI YUKA YAKUHIN KK 1982-03-20 JP disclosed
JP-S5653659-A BLOOD PLATELET COAGULATION SUPPRESSING AGENT MITSUBISHI YUKA YAKUHIN KK 1981-05-13 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 MAPT 2358/4885ALDH1A1 1859/4885SMN1; SMN2 2432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.